Photo credit: Rachel Gross
Paul Hudson occupied the CEO’s office at Sanofi, one of the largest healthcare companies in the world, with deep roots in scientific research and—in large part due to Hudson—a growing focus on AI-powered drug development.
Under Hudson’s leadership, Sanofi shifted its focus to R&D in high-value therapeutic areas such as immunology, rare diseases, and specialty care. That shift allowed him to boost Sanofi’s sales growth by 7% and add several new medicines to its portfolio, including Altuviiio, a treatment for hemophilia A, a genetic bleeding disorder whose victims suffer from insufficient blood clotting.
Hudson also stood out as one of the most vocal and hands-on advocates for AI in the pharmaceutical industry. He didn’t delegate this strategy; instead, he took personal charge of Sanofi’s AI adoption and its use of agentic AI to accelerate drug discovery and streamline operations.
With a track record like that, it’s no wonder he became such a standout figure in the global healthcare conversation.
